You are here

Clinical Trials

The Department of Surgery doesn’t just excel in the operating room. Through our extensive and innovative research programs, we are also focused on the development of new techniques and therapies that promote better outcomes and improve the quality of life for patients following surgery. 

As part of that goal, the department’s surgeons are involved in groundbreaking clinical trials. In addition to their research value, clinical trials may also give patients access to new treatments that are not available anywhere else.

Learn more about our current clinical trials below or visit the Joint Clinical Trials Office at Weill Cornell Medicine and NewYork-Presbyterian.

This is a prospective, multi-center, observational study designed to determine if specific agents used for treatment of inflammatory bowel disease (IBD) are associated with the development of new or recurrent cancer in patients with IBD and a history of cancer.

Key Inclusion / Exclusion Criteria:
  • Age 18 or older at entry
  • Diagnosis of Crohn’s disease, ulcerative colitis, or indeterminate colitis
  • Have IBD and a diagnosis of a new or prior cancer diagnosis within the last 5 years

Exclusion Criteria

  • Current enrollment in a clinical trial of an investigational therapy for Crohn’s disease or ulcerative colitis
  • IBD patients with a cancer diagnosis > 5 years prior to study entry
  • IBD patients with active chemotherapy or radiation cancer treatment at enrollment


This clinical trial is open for men and women with Crohn’s disease whose physician has determined that these patients will begin taking Cimzia® (certolizumab pegol) or another medication to treat Crohn’s disease. 

The purpose of this study is to see if a new study drug, called semaglutide, has an effect on reducing the risk of cardiovascular (CV) events (e.g. heart attack and stroke) in subjects with overweight or obesity and with prior cardiovascular disease.

Key Inclusion / Exclusion Criteria:
  • Male or female, age 45 or older 
  • Body mass index (BMI) of 27 kg/m2 or higher 
  • No history of type 1 or type 2 diabetes (history of gestational diabetes is allowed) 
  • Established CV disease as evidenced by at least one of the following: 

- prior myocardial infarction 
- prior stroke (ischemic or haemorrhagic stroke) 
- symptomatic peripheral arterial disease (PAD) or peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease 

This clinical trial is for men and women with unresectable locally-advanced or metastatic triple-negative breast cancer. There is currently a need for more effective treatment methods for this disease. 

Key Inclusion / Exclusion Criteria:
  • Open to men and women age 18 and older 
  • Diagnosed with unresectable locally-advanced or metastatic triple-negative breast cancer 
  • Detailed eligibility will be reviewed when you contact the study team 

The study will enroll subjects during their heart failure (HF) admission (i.e. with acute decompensated HF). These patients are at an increased risk for hospital readmissions- as it had been demonstrated in several studies.

Key Inclusion / Exclusion Criteria:
  • Men and women 21 years of age or older
  • Diagnosis of HF made at least 90 days prior to enrollment
  • Patient is hospitalized for ADHF requiring treatment with IV diuretics or vasoactive drugs
  • HF patient with Class D objective assessment are not eligible
  • Cardiac transplantation or VAD implantation patients are excluded
  • BMI above 22 and lower than 36
  • Detailed eligibility reviewed with the research team

This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells.

This is a prospective, multi-center, treatment registry study of patients who are being treated with IVIG as part of clinical care to prevent DSA post-kidney transplant.

Pacemakers are electronic devices that are designed to prevent the heart from going too slowly. They are used primarily in people whose normal pacemakers are either diseased or suppressed by drugs, or in whom the connection between the upper and lower chambers of the heart---what’s called the car

Key Inclusion / Exclusion Criteria:
  • People who have been or intend to be implanted with a complete SureScan Pacing System consisting of both a right atrial and ventricular 5086 MRI lead (used for pacing and sensing) and a SureScan device

This research study is for men and women who will be implanted with a pacemaker for the treatment of bradycardia or atrial tachycardia and choose a SureScan pacemaking system in consultation with their physician.

Find a Physician

Surgical Services
Weill Cornell Medicine Surgery

Visit our Surgery YouTube channel to view our video library.